SCRT+mFOLFOX6+PD-1 Antibody and Targeted Therapy for High-Risk pMMR/MSS Rectal Cancer(CRIT)

Sponsor
Sixth Affiliated Hospital, Sun Yat-sen University
Study ID
NCT06908031
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • High-Risk Cancer
  • MSS
  • Rectal Adenocarcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Short-Course Radiotherapy — RADIATION
    Patients undergo SCRT at a dose of 5Gy × 5 fractions
  • PD-1 monoclonal antibody — DRUG
    Patients complete immune therapy with PD-1 monoclonal antibody for 4 cycles.
  • mFOLFOX6 regimen — DRUG
    Patients complete chemotherapy with mFOLFOX6 regimen for 4 cycles.
  • Cetuximab — DRUG
    Patients with RAS/BRAF wild-type receive targeting therapy with Cetuximab for 4 cycles.
  • Bevacizumab — DRUG
    Patients with RAS/BRAF mutations receive targeting therapy with Bevacizumab for 3 cycles. (Bevacizumab is not used in the last cycle of the bevacizumab group)
  • Surgical resection — PROCEDURE
    Surgery either local excition or total mesorectal excision is performed 8-10 weeks after the completion of short-course radiotherapy.

Study Details

To explore the efficacy and safety of short-course radiotherapy combined with mFOLFOX6, PD-1 monoclonal antibody and cetuximab (for RAS/BRAF Wild-Type)/bevacizumab (for RAS/BRAF Mutant) in High-Risk pMMR/MSS Rectal Adenocarcinoma through a prospective study, providing high-level evidence-based medical evidence for the use in the treatment of high-risk rectal cancer.

Key Dates

First listed
Apr 3, 2025
Start date
Apr 2, 2025
Status verified
Jun 2026
Primary completion
Apr 1, 2027
Completion
Apr 1, 2027

Study Design

Enrollment
49 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: SCRT + mFOLFOX6 + PD-1 Antibody + Targeted Therapy
    The neoadjuvant treatment phase includes short-course radiotherapy (SCRT) combined with four cycles of the mFOLFOX6 regimen, PD-1 monoclonal antibody, and molecularly targeted drugs (selected based on RAS status; patients with RAS/BRAF wild-type receive cetuximab, while those with RAS/BRAF mutations receive bevacizumab). After completing the first cycle of mFOLFOX6 chemotherapy combined with targeted and immune therapy, patients undergo SCRT at a dose of 5Gy × 5 fractions. At least 7 days after the completion of radiotherapy, patients continue with three additional cycles of mFOLFOX6 chemotherapy combined with PD-1 monoclonal antibody and targeted drugs (bevacizumab is not used in the last cycle of the bevacizumab group). Surgery is performed 8-10 weeks after the completion of SCRT.

Primary Outcome Measure

Pathological Complete Response [ Time Frame: 1 year ]

Central Contacts

Related Studies